Bioptimus, a Paris-based artificial intelligence and biotech company, said it has partnered with the UK’s Cancer Research Horizons to access a multimodal colorectal cancer dataset covering more than 1,750 patient profiles.
Under the terms of the deal, Bioptimus will use Stratification in COloRectal cancer Trial (S:CORT) data to train and evaluate its Spatial Tissue Embedding Learning Atlas (STELA) AI foundation model. The dataset, assembled from multiple UK patient cohorts, integrates as many as six data modalities per patient, pairing molecular and cellular profiling with longitudinal clinical outcomes.
“Building AI models that genuinely move the needle for cancer patients requires data of exceptional depth and quality,” said Jean-Philippe Vert, chief executive officer of Bioptimus. “The S:CORT dataset, with its rich combination of imaging, genomic, transcriptomic, and clinical data, is exactly the kind of resource that allows us to rigorously evaluate and continue the development of M-Optimus to deliver real-world clinical advancements.”
Bioptimus added that S:CORT data will serve as a key evaluation benchmark. Financial and other details were not disclosed.
Cancer Research Horizons is part of Cancer Research UK. The agreement is Bioptimus’ third partnership under the STELA initiative since its launch five months ago.
In June, Bioptimus signed a similar agreement for access to gastrointestinal cancer data with France’s Fédération Francophone de Cancérologie Digestive (FFCD).
Bioptimus to Expand AI-Based Tissue Atlas with French GI Cancer Network
French artificial intelligence startup Bioptimus has signed a partnership with the Fédération Francophone de Cancérologie Digestive (FFCD), a French academic cancer research organization, granting the Paris-based biotech access to a cohort of clinical trial data from more than 3,000 gastrointestinal (GI) cancer patients.